Gene and drug matrix for personalized cancer therapy

Nature Reviews Drug Discovery

Volumn 9, Issue 8, 2010, Pages 660-

  Harris, Tim ^a  

^a SAIC FREDERICK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AURORA A KINASE; AURORA B KINASE; B RAF KINASE; BCR ABL PROTEIN; CD135 ANTIGEN; CRIZOTINIB; CYCLIN DEPENDENT KINASE 5; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; EVEROLIMUS; GEFITINIB; IMATINIB; JANUS KINASE 2; K RAS PROTEIN; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; NILOTINIB; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PLX 4032; PROTEIN KINASE B; PROTEIN RET; SORAFENIB; STEM CELL FACTOR RECEPTOR; SUNITINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BREAST CANCER; CANCER RESISTANCE; CHRONIC MYELOID LEUKEMIA; COLON CANCER; DRUG TARGETING; ENZYME INHIBITION; GENE EXPRESSION; GENE MUTATION; HUMAN; LETTER; LUNG CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; PHARMACOGENETICS; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; DECISION MAKING; DNA, NEOPLASM; DRUG DESIGN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS; SEQUENCE ANALYSIS, DNA;

EID: 77955132745     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3181-c1     Document Type: Letter

References (10)

1. Schilsky, R. Personalized medicine in oncology: thefuture is now. Nature Rev. Drug Discov. 9, 363-367(2010).
2. Harris, T. J. R. & McCormick, F. The molecularpathology of cancer. Nature Rev. Clin. Oncol. 7,251-265 (2010).
3. MacConnaill, L. E. et al. Profiling critical cancer genemutations in clinical tumour samples. PLoS One 4,e7887 (2009).
4. Munroe, D. J. & Harris T. J. R. Third generationsequencing fireworks at Marco Island. Nature Biotech. 28, 426-428 (2010).
5. Zhang, J., Yang, P. L. & Gray, N. S. Targeting cancerwith small molecule kinase inhibitors. Nature Rev. Cancer 9, 28-39 (2009).
6. Garber, K. Melanoma drug vindicates targetedapproach. Science 326, 1619 (2009).
7. Mosse, Y. P., Wood, A. & Maris, J. M. Inhibition of ALKsignalling for cancer therapy. Clin. Cancer Res. 15,5609-5614 (2009).
8. Li, J. et al. A chemical and phosphoproteomiccharacterisation of dasatanib action in lung cancerNature Chem. Biol. 6, 291-299 (2010).
9. Bukowski, R. M., Yasothan, U. & Kirkpatrick, P. Pazopanib. Nature Rev. Drug Discov. 9, 17 (2010).
10. Engelman, J. A. et al. MET amplification leads togefitinib resistance in lung cancer by activating ERBB3signalling. Science 316, 1039-1043 (2007).